The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Immuneering Corp (NASDAQ: IMRX) closed at $1.80 up 1.69% from its previous closing price of $1.77. In other words, the price has increased by $1.69 from its previous closing price. On the day, 0.52 million shares were traded. IMRX stock price reached its highest trading level at $1.82 during the session, while it also had its lowest trading level at $1.56.
Ratios:
For a deeper understanding of Immuneering Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.35 and its Current Ratio is at 11.35. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 15, 2024, Reiterated its Buy rating but revised its target price to $15 from $20 previously.
Jefferies Downgraded its Buy to Hold on March 15, 2024, whereas the target price for the stock was revised from $16 to $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 01 ’24 when Cormorant Asset Management, LP sold 400,000 shares for $2.90 per share. The transaction valued at 1,160,181 led to the insider holds 2,895,273 shares of the business.
Feinberg Peter bought 25,000 shares of IMRX for $63,713 on Mar 22 ’24. The Director now owns 111,766 shares after completing the transaction at $2.55 per share. On Mar 22 ’24, another insider, Brakewood Harold Eugene, who serves as the Chief Business Officer of the company, bought 3,900 shares for $2.57 each. As a result, the insider paid 10,015 and bolstered with 3,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMRX now has a Market Capitalization of 52709940 and an Enterprise Value of -28492836.
Stock Price History:
The Beta on a monthly basis for IMRX is -0.61, which has changed by -0.84375 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, IMRX has reached a high of $14.29, while it has fallen to a 52-week low of $1.75. The 50-Day Moving Average of the stock is -58.49%, while the 200-Day Moving Average is calculated to be -73.55%.
Shares Statistics:
For the past three months, IMRX has traded an average of 681.30K shares per day and 594920 over the past ten days. A total of 29.27M shares are outstanding, with a floating share count of 20.63M. Insiders hold about 29.56% of the company’s shares, while institutions hold 38.49% stake in the company. Shares short for IMRX as of 1711584000 were 2875898 with a Short Ratio of 4.22, compared to 1709164800 on 2684594. Therefore, it implies a Short% of Shares Outstanding of 2875898 and a Short% of Float of 18.34.
Earnings Estimates
The market rating of Immuneering Corp (IMRX) is currently shaped by the ongoing analysis conducted by 7 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.5 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.59, while EPS last year was -$0.51. The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.23 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$0.93 and -$2.29 for the fiscal current year, implying an average EPS of -$1.89. EPS for the following year is -$1.92, with 7 analysts recommending between -$0.83 and -$2.62.
